ImmuCell (ICCC) to Announce Earnings on Thursday

ImmuCell (NASDAQ:ICCC) is expected to be issuing its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $5.4010 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:00 AM ET.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.05 by $0.16. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%. The business had revenue of $10.36 million for the quarter, compared to analyst estimates of $5.40 million.

ImmuCell Trading Down 0.3%

Shares of ImmuCell stock opened at $10.97 on Tuesday. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.82 and a quick ratio of 2.60. ImmuCell has a 1 year low of $4.52 and a 1 year high of $12.10. The company has a market capitalization of $99.25 million, a P/E ratio of -182.80 and a beta of 0.54. The business has a 50 day moving average price of $10.44 and a 200 day moving average price of $8.41.

Insiders Place Their Bets

In related news, CEO Boekhorst Paul Francis Oliv Te bought 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The shares were acquired at an average cost of $9.49 per share, with a total value of $75,920.00. Following the completion of the transaction, the chief executive officer owned 17,785 shares of the company’s stock, valued at approximately $168,779.65. The trade was a 81.76% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On ImmuCell

A hedge fund recently raised its position in ImmuCell stock. Geode Capital Management LLC grew its stake in shares of ImmuCell Corporation (NASDAQ:ICCC) by 4.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 71,852 shares of the biotechnology company’s stock after buying an additional 2,907 shares during the period. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 13.47% of the company’s stock.

Analyst Ratings Changes

ICCC has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmuCell in a research report on Thursday, July 2nd. Wall Street Zen raised shares of ImmuCell to a “strong-buy” rating in a research note on Saturday, June 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.